METHODS OF TREATMENT FOR ULCERATIVE COLITIS USING AMINOSALICYLATE
Disclosed herein is a new treatment for ulcerative colitis in male mammalian subjects. Further disclosed are increased dosages of an aminosalicylate composition for treatment of moderate ulcerative colitis in male mammalian subjects.
1 . A method of treating moderate ulcerative colitis in a mammalian male subject comprising the step of administering to said mammalian male subject an aminosalicylate in an amount to deliver greater than about 2.4 g/day of 5-aminosalicylic acid to said subject.
2 . The method of claim 1 , wherein the mammalian male subject is a human male.
3 . The method of claim 2 , comprising the step of orally administering to said mammalian male subject an aminosalicylate in an amount to deliver greater than about 2.4 g/day but less than or equal to about 4.8 g/day of 5-aminosalicylic acid to said subject.
4 . The method of claim 3 , wherein said step of orally administering an aminosalicylate comprises orally administering an aminosalicylate in an amount to deliver about 4.8 g/day of 5-aminosalicylic acid to said subject.
5 . The method of claim 4 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
6 . The method of claim 5 , wherein said step of orally administering comprises orally administering once per day, twice per day, three times per day, or four times per day.
7 . The method of claim 3 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
8 . The method of claim 3 , wherein said aminosalicylate comprises mesalamine and further wherein said mesalamine is administered in an amount of about 4.8 g/day.
9 . The method of claim 3 , wherein said mammalian male subject is less than 65 years of age.
10 . The method of claim 3 , wherein said mammalian male subject is a non-smoking subject.
11 . The method of claim 3 , wherein said mammalian male subject is Caucasian.
12 . The method of claim 3 , wherein said mammalian male subject is a previous or current steroid user.
13 . The method of claim 3 , wherein said step of orally administering comprises orally administering a tablet comprising about 800 milligrams of mesalamine or a salt thereof.
14 . The method of claim 13 , wherein said tablet is a delayed-release tablet.
15 . The method of claim 3 , wherein said aminosalicylate comprises a component selected from the group consisting of mesalamine, salts of mesalamine, olsalazine, salts of olsalazine, balsalazide, salts of balsalazide, sulfasalazine, salts of sulfasalazine, and mixtures thereof.
16 . The method of claim 3 , wherein said step of orally administering comprises orally administering once per day, twice per day, three times per day, or four times per day.
17 . The method of claim 2 , wherein step of administering comprises rectal administration.
18 . The method of claim 17 , wherein said step of administering an aminosalicylate comprises administering an aminosalicylate in an amount to deliver about 4.8 g/day of 5-aminosalicylic acid to said subject.
19 . The method of claim 18 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
20 . The method of claim 19 , wherein said step of administering comprises administering once per day, twice per day, three times per day, or four times per day.
21 . The method of claim 17 , wherein said aminosalicylate comprises mesalamine or a salt thereof.
22 . The method of claim 17 , wherein said mammalian male subject is less than 65 years of age.
23 . The method of claim 17 , wherein said mammalian male subject is a non-smoking subject.
24 . The method of claim 17 , wherein said mammalian male subject is Caucasian.
25 . The method of claim 17 , wherein said mammalian male subject is a previous or current steroid user.
26 . The method of claim 17 , wherein said step of administering comprises administering a rectal composition comprising about 800 milligrams or about 1.2 g of mesalamine or a salt thereof.
27 . The method of claim 17 , wherein said rectal composition is an enema.
28 . The method of claim 17 , wherein said rectal composition is a foam.
29 . The method of claim 17 , wherein said aminosalicylate comprises a component selected from the group consisting of mesalamine, a salt of mesalamine, olsalazine, a salt of olsalazine, balsalazide, a salt of balsalazide, sulfasalazine, a salt of sulfasalazine, or any pharmaceutically acceptable combination thereof.
30 . The method of claim 29 , wherein said step of administering comprises administering once per day, twice per day, three times per day, or four times per day.